Charles River Labs Director Departs; Officer Comp & Reg FD Disclosed

TL;DR

CRLV director Jim Mullen out, company filed Reg FD and officer comp details.

AI Summary

Charles River Laboratories International, Inc. announced on September 12, 2025, the departure of Director James C. Mullen. The company also reported on compensatory arrangements for certain officers and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.

Why It Matters

Changes in directorship can signal shifts in company strategy or governance, while regulatory disclosures are crucial for investors to understand the company's communications.

Risk Assessment

Risk Level: low — This filing primarily concerns director departures and routine disclosures, with no immediate financial impact indicated.

Key Players & Entities

• Charles River Laboratories International, Inc. (company) — Registrant
• James C. Mullen (person) — Departing Director
• September 12, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common stock, $0.01 par value CRL New York Stock Exchange

Filing Documents

• dp234367_8k.htm (8-K) — 26KB
• dp234367_ex9901.htm (EX-99.1) — 19KB
• image_002.jpg (GRAPHIC) — 4KB
• 0000950103-25-011676.txt ( ) — 217KB
• crl-20250912.xsd (EX-101.SCH) — 3KB
• crl-20250912_lab.xml (EX-101.LAB) — 33KB
• crl-20250912_pre.xml (EX-101.PRE) — 22KB
• dp234367_8k_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On September 12, 2025, Flavia H. Pease informed Charles River Laboratories International, Inc. (the "Company") of her intention to resign from her position as the Company's Corporate Executive Vice President, Chief Financial Officer effective on September 29, 2025. Ms. Pease's decision to resign her position is not the result of any disagreements with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices. (c) In connection with Ms. Pease's departure from the position of Chief Financial Officer, Michael G. Knell, Corporate Senior Vice President and Chief Accounting Officer, has been appointed by the Company's Board of Directors to act as the Company's interim Chief Financial Officer, effective upon the departure of Ms. Pease, until a permanent successor is named. In this role, Mr. Knell will serve as the Company's principal financial officer. Mr. Knell, age 49, joined the Company in April 2017 as Corporate Senior Vice President and Chief Accounting Officer. In this role, Mr. Knell is responsible for providing strategic guidance to the finance groups, including direction of the Global Accounting, Financial Planning and Analysis, and Tax functions; maintaining the Company's fiscal records; and preparing its financial reports. He also oversees the design and operation of the Company's system of internal controls, ensuring compliance with the rules and regulations of the Sarbanes-Oxley Act. Prior to joining the Company, Mr. Knell served as the Chief Accounting Officer and Vice President of Finance at Bruker Corporation from 2012 to 2017. Mr. Knell was with Ernst & Young LLP in its Boston office from 1998 until 2011, where he served in various roles including Partner - Assurance Services. Mr. Knell is a Certified Public Acc

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On September 16, 2025, the Company issued a press release announcing Ms. Pease's departure and Mr. Knell's appointment. A copy of the press release is attached as Exhibit 99.1 hereto. The press release, attached as an exhibit to this report, includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain and other risks relating to the Company are set forth in the documents filed by the Company with the Securities and Exchange Commission. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of Charles River Laboratories International, Inc., dated as of September 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Date: September 16, 2025 By: /s/ Matthew L. Daniel Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer

View Full Filing

View this 8-K filing on SEC EDGAR